3.62 USD
0.000.00%
盘后 3.58 -1.10%
2026-09-15
市值
$348.01M
市盈率
—
EPS
-0.89
股息率
—
52 周区间
2.80 – 4.83
成交量
2.08M
Beta
0.39
目标价
11.60
52W 低 2.8052W 高 4.83
价格走势
公司简介
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Ta...